Shares of HUTCHMED (China) Limited (NASDAQ:HCM – Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $17.52, but opened at $18.40. HUTCHMED shares last traded at $18.31, with a volume of 20,671 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded HUTCHMED from a “hold” rating to a “buy” rating in a report on Monday, June 10th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.70.
View Our Latest Stock Analysis on HCM
HUTCHMED Stock Performance
Hedge Funds Weigh In On HUTCHMED
Several large investors have recently modified their holdings of HCM. M&G Plc purchased a new position in HUTCHMED in the 1st quarter worth about $4,458,000. Hsbc Holdings PLC grew its stake in shares of HUTCHMED by 821.2% in the fourth quarter. Hsbc Holdings PLC now owns 206,544 shares of the company’s stock worth $3,720,000 after acquiring an additional 184,123 shares during the period. Bellevue Group AG raised its holdings in shares of HUTCHMED by 2.1% during the first quarter. Bellevue Group AG now owns 1,154,632 shares of the company’s stock valued at $19,398,000 after purchasing an additional 23,521 shares during the last quarter. BNP Paribas Financial Markets lifted its position in HUTCHMED by 54.9% during the first quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company’s stock valued at $721,000 after purchasing an additional 15,221 shares during the period. Finally, Baillie Gifford & Co. boosted its holdings in HUTCHMED by 7.2% in the fourth quarter. Baillie Gifford & Co. now owns 144,969 shares of the company’s stock worth $2,625,000 after purchasing an additional 9,694 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.
HUTCHMED Company Profile
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Featured Stories
- Five stocks we like better than HUTCHMED
- How to Start Investing in Real Estate
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- Trading Stocks: RSI and Why it’s Useful
- Qualcomm Stock Continues to Rise in the Face of Negative News
- How to Find Undervalued Stocks
- Top 3 Summer Stocks with Solid Growth Opportunities
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.